ERBB2 and breast cancer: For 77 patients with Her2-positive or TN BC, DFS in multivariate analysis was significantly associated with omission of cALND (HR: 38.451, CI 95% 1.437–1028, p = 0.030) and no radiotherapy (HR: 7.824, CI 95% 1.246–49.118, p = 0.028) (Table 7, Figure 2).